Monitor whether WW can stabilize its Behavioral subscriber base while scaling its higher-ARPU Clinical segment. The stock may react to early 2026 subscriber trends and marketing efficiency, especially given the planned reduction in post-Q1 marketing spend.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 16 $21.20entry
- T+1 · 8mo ago −12.17%α −12.44% · $18.62
- T+5 · 8mo ago −15.28%α −13.24% · $17.96
- T+20 · 7mo ago −49.76%α −53.54% · $10.65
- T+60 · 5mo ago −18.92%α −29.40% · $17.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
WW International reported Q4 2025 results with total revenue of $162.8 million, down 12% year-over-year, driven by secular declines in its Behavioral business. However, Clinical Subscription Revenue surged 32% YoY to $27 million, with Clinical subscribers up 42% to 130 thousand. The company exceeded 2025 Adjusted EBITDA guidance and provided 2026 revenue guidance of $620–635 million and Adjusted EBITDA of $105–115 million, signaling a strategic shift toward integrated GLP-1 and behavioral health solutions.
Key Financial Metrics
Key Facts
- Q4 2025 Total Revenue: $162.8 million, down 12% YoY
- Q4 Clinical Subscription Revenue: $27 million, up 32% YoY
- End of Period Clinical Subscribers: 130 thousand, up 42% YoY
- Q4 Net Loss: $5.8 million (3.6% margin), Adjusted EBITDA: $18.0 million (11.1% margin)
- 2026 Full Year Guidance: Revenue $620–635 million, Adjusted EBITDA $105–115 million
- Company emerged from Chapter 11 in June 2025 and applied fresh start accounting
Financial Impact
Revenue decline of 12% YoY in Q4, but Clinical segment growing rapidly; 2026 revenue guidance implies ~12-15% decline from 2025's $710.6 million
Risk Factors
- Continued erosion of Behavioral business may offset Clinical growth
- Heavy reliance on future Clinical subscriber growth and ARPU expansion
- Execution risk in transitioning to integrated weight health model
- Guidance implies continued revenue contraction in 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256124 |
Track record
20 reports on WW
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +9.16% at T+20 after the Apr 3, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $9.46 Now $9.46 +0.00% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $10.84 Now $9.46 −12.73% settles Dec 15
- Nov 10, 20266d ago Insider Cluster Bullish 4/10 Entry $13.05 Now $9.46 −27.51% settles Dec 10
- Nov 5, 202611d ago 8-K Mixed 6/10 Entry $12.84 Now $9.46 −26.32% settles Dec 4
- Oct 13, 20264w ago SC 13G/A Bearish 4/10 Entry $14.27 to $13.05 Now $9.46 +33.71% ▲ +8.55% +7.28% vs SPY
- Sep 9, 20269w ago 8-K Neutral 4/10 Entry $14.94 to $15.08 Now $9.46 −36.68% ▲ +0.94% −1.01% vs SPY
- Aug 20, 202612w ago Insider Buy Bullish 5/10 Entry $15.71 to $16.39 Now $9.46 −39.78% ▲ +4.33% +4.85% vs SPY
- Jul 23, 202616w ago Press Release Neutral 1/10 Entry $13.34 to $15.71 Now $9.46 −29.09% ▲ +17.77% +14.14% vs SPY
- Jun 16, 202621w ago Press Release Bullish 5/10 Entry $19.05 to $14.87 Now $9.46 −50.34% ▼ −21.94% −23.26% vs SPY
- Jun 4, 202623w ago DEFA14A Neutral 5/10 Entry $17.27 to $16.31 Now $9.46 −45.21% ▼ −5.53% −4.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers